NCT07151937View on ClinicalTrials.gov

A Study of LAD191 in Adults With Hidradenitis Suppurativa

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2027

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

LAD191

LAD191 subcutaneous injection.

OTHER

Placebo

LAD191 Placebo subcutaneous injection.

DRUG

Adalimumab

Adalimumab subcutaneous injection.

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY